CClinicalTrials.gg
Status unknownNCT05499364Updated Aug 16, 2022

TinCat LGBTQ+ Smoking Cessation Via Asynchronous Telehealth

An interventional study of TinCat and Quit.gov program in Tobacco Use Disorder and Tobacco Use Cessation, sponsored by University of Texas at Austin. Status unknown. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by University of Texas at Austin · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy of a novel telehealth-based intervention to reduce tobacco use among LGBTQ+ people.

Read the detailed description

After being informed about potential risks and screened into the study, patients will be randomized into the treatment or control group. Control group participants will complete 7 sessions based on quit.gov smoking cessation planning. Intervention participants will complete 7 sessions of individualized asynchronous telehealth sessions.

02

Conditions studied

  • Tobacco Use Disorder
  • Tobacco Use Cessation

Browse trials for

03

In context

Tobacco Use Disorder

968 studies on the registry are indexed under Tobacco Use Disorder; 126 are open to participants now.

This study's planned enrollment of 30 is below the median of 89 across 851 interventional studies indexed under Tobacco Use Disorder.

Browse Tobacco Use Disorder studies →

Lead sponsor

University of Texas at Austin is the lead sponsor of 319 studies on the registry; 78 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18 and over
  • Live in Greater Austin
  • Identify as LGBTQ+
  • Current smokers
  • High speed internet access

Exclusion criteria

Exclusion Criteria:

  • Exceed screener cutoff for suicide risk
  • Exceed screener cutoff for borderline personality disorder
  • Report current active substance use other than tobacco that interferes with functioning
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Quit.gov program

    Generic intervention based on quit.gov sessions.

    Behavioral: Quit.gov program

  • Experimental
    TinCat

    Individualized asynchronous telehealth including LGBTQ+ affirming components.

    Behavioral: TinCat

Interventions

  • BehavioralTinCat

    7-10 minute personalized video sessions based in tobacco cessation modules.

  • BehavioralQuit.gov program

    7-10 minute generic videos directing participants through quit.gov program

06

What researchers measure

Primary outcomes

  1. Tobacco use

    Cigarette and vape assessments based on prior research on vaping/smoking: Cigarette: Today, did you have at least one puff on a cigarette (yes/no) IF YES, THEN How many cigarettes did you smoked (at least one puff) (1-"more than 60"). Vaping: Today, did you use an electronic nicotine delivery system (i.e., a vape containing nicotine), even just one puff? (yes/no) IF YES, THEN How many times they had at least one puff (1 time, 2-5 times, 6-10 times, 11-15 times, 16-20 times, 21-25 times, 26-30 times, 31 or more times).

    Time frame: 11 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Teah GE, Conner TS. Psychological and Demographic Predictors of Vaping and Vaping Susceptibility in Young Adults. Front Psychol. 2021 Aug 17;12:659206. doi: 10.3389/fpsyg.2021.659206. eCollection 2021. Erratum In: Front Psychol. 2022 Apr 22;13:871241. doi: 10.3389/fpsyg.2022.871241. PubMed 34484026 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05499364
Lead sponsor
University of Texas at Austin
Responsible party
Michael Parent (Associate professor, University of Texas at Austin) — Principal investigator
First posted
Aug 12, 2022
Start date
Jan 1, 2023 (estimated)
Primary completion
Apr 30, 2023 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Aug 16, 2022

Study contacts

Mike Parent, PhD
Contact
michael.parent@austin.utexas.edu
352-642-2404

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion